Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 77 of the 78 references it cites were found in a registry or an index.

Widespread genomic influences on phenotype in Dravet syndrome, a ‘monogenic’ condition

Open access
Martins Custodio, Helena, Clayton, Lisa M, Bellampalli, Ravishankara, Pagni, Susanna, Silvennoinen, Katri, Caswell, Richard, Genomics England Research Consortium, Ambrose, John C, Arumugam, Prabhu, Bevers, Roel, Bleda, Marta, Boardman-Pretty, Freya, Boustred, Christopher R, Brittain, Helen, Brown, Matthew A, Caulfield, Mark J, Chan, Georgia C, Giess, Adam, Griffin, John N, Hamblin, Angela, Henderson, Shirley, Hubbard, Tim J P, Jackson, Rob, Jones, Louise J, Kasperaviciute, Dalia, Kayikci, Melis, Kousathanas, Athanasios, Lahnstein, Lea, Lakey, Anna, Leigh, Sarah E A, Leong, Ivonne U S, Lopez, Javier F, Maleady-Crowe, Fiona, McEntagart, Meriel, Minneci, Federico, Mitchell, Jonathan, Moutsianas, Loukas, Mueller, Michael, Murugaesu, Nirupa, Need, Anna C, O'Donovan, Peter, Odhams, Chris A, Patch, Christine, Perez-Gil, Daniel, Pereira, Marina B, Pullinger, John, Rahim, Tahrima, Rendon, Augusto, Rogers, Tim, Savage, Kevin, Sawant, Kushmita, Scott, Richard H, Siddiq, Afshan, Sieghart, Alexander, Smith, Samuel C, Sosinsky, Alona, Stuckey, Alexander, Tanguy, Mélanie, Tavares, Ana Lisa Taylor, Thomas, Ellen R A, Thompson, Simon R, Tucci, Arianna, Welland, Matthew J, Williams, Eleanor, Witkowska, Katarzyna, Wood, Suzanne M, Zarowiecki, Magdalena, Brunklaus, Andreas, Guerrini, Renzo, Koeleman, Bobby P C, Lemke, Johannes R, Møller, Rikke S, Scheffer, Ingrid E, Weckhuysen, Sarah, Zara, Federico, Zuberi, Sameer, Kuchenbaecker, Karoline, Balestrini, Simona, Mills, James D, Sisodiya, Sanjay M · 2023 · Brain

Abstract

Dravet syndrome is an archetypal rare severe epilepsy, considered ‘monogenic’, typically caused by loss-of-function SCN1A variants. Despite a recognizable core phenotype, its marked phenotypic heterogeneity is incompletely explained by differences in the causal SCN1A variant or clinical factors. In 34 adults with SCN1A-related Dravet syndrome, we show additional genomic variation beyond SCN1A contributes to phenotype and its diversity, with an excess of rare variants in epilepsy-related genes as a set and examples of blended phenotypes, including one individual with an ultra-rare DEPDC5 variant and focal cortical dysplasia. The polygenic risk score for intelligence was lower, and for longevity, higher, in Dravet syndrome than in epilepsy controls. The causal, major-effect, SCN1A variant may need to act against a broadly compromised genomic background to generate the full Dravet syndrome phenotype, whilst genomic resilience may help to ameliorate the risk of premature mortality in adult Dravet syndrome survivors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/brain/awad111

Cites

77 of 77 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Method for selection of variants in epilepsy-related genes. Method for selection of variants in epilepsy-related genes with ‘potential clinical relevance’ that may contribute to blended phenotypes. GEL = Genomics England.
Figure 1 Method for selection of variants in epilepsy-related genes. Method for selection of variants in epilepsy-related genes with ‘potential clinical relevance’ that may contribute to blended phenotypes. GEL = Genomics England.CC BY · PubMed Central
Figure 2 Distribution of SCN1A variants found in the Dravet syndrome cohort. A schematic diagram of the SCN1A gene. Exons are indicated by vertical black boxes (1–29) and introns by the horizontal black line (not to scale). Missense (purple), splicing (dark blue), frameshift insertion (light blue), frameshift deletion (green) and stop-gain (red) variants are shown. The whole gene deletion is not shown. Variants are shown according to the NM_001165963.4 reference sequence.
Figure 2 Distribution of SCN1A variants found in the Dravet syndrome cohort. A schematic diagram of the SCN1A gene. Exons are indicated by vertical black boxes (1–29) and introns by the horizontal black line (not to scale). Missense (purple), splicing (dark blue), frameshift insertion (light blue), frameshift deletion (green) and stop-gain (red) variants are shown. The whole gene deletion is not shown. Variants are shown according to the NM_001165963.4 reference sequence.CC BY · PubMed Central
Figure 3 FCD and details of DEPDC5 variant. (A) Brain MRI showing FCD. Coronal T1-weighted brain MRI from Case 1-102398, with DEPDC5 variant NM_001242896.3:c.G4183A:p.A1395T, showing left temporal lobe FCD (right of patient is on the left of the image, following radiological convention), with blurred grey–white interface and cortical thickening apparent in the left temporal lobe across several consecutive slices. (B) MetaDome map of regional constraint in DEPDC5. Grey bar below the graph represents the protein, pink bars showing Pfam domains: PF12257, Vacuolar membrane-associated protein Iml1 domain; PF00610, Domain found in Dishevelled, Egl-10, and Pleckstrin (DEP); A1395 is marked by a vertical green line, with a reported tolerance score of 0.28 (‘intolerant’). (C) VarSite sequence logo for DEPDC5 residues 1375–1414, based on alignment of structural homologues; below the logo is the sequence of DEPDC5 itself, with A1395 boxed; sequence conservation score for this residue was 0.92 [range 0 (low)–1 (high)]; alanine was observed at this position in 31/33 aligned sequences. (D) Structure of the GATOR1-Rag GTPases complex and context of DEPDC5 Ala1395. PDB 6ces, the structure of the heterotrimeric GATOR1 complex (DEPDC5:NPRL2:NPRL3) bound to RagA and RagC GTPases; protein surfaces shown by colour as indicated (except DEPDC5, shown as a ribbon and coloured by structural domains as annotated by Shen et al.39: bright green = N-terminal domain (NTD) (residues 38–165); cyan = SABA domain (166–425); orange = steric hindrance for enhancement of nucleotidase activity (SHEN) domain (721–1010); dark green = DEP domain (1175–1270); violet = C-terminal domain (CTD) (1271–1600); Ala1395 is pink with sidechain atoms shown as spheres. (E and F) Ala1395 lies at an inter-domain interface in DEPDC5. The figure shows selected residues of DEPDC5 from PDB 6ces (chain D); residues of the NTD, SABA domain and CTD are shown as separate surfaces; residues of the SHEN domain and DEP domain are shown as ribbons. F shows the same structure as E with SHEN and DEP domains removed; residues Tyr108 (bright green), Phe326 (blue) and Ala1395 (rose pink) lie in close proximity at a three-way interface between the NTD, SABA and CTD. (G) Enlarged image of the DEPDC5 structure (PDB 6ces, chain D) as in E and F, zoomed to show detail around the three-way interface between the NTD, SABA and CTD; (H) The Ala1395Thr substitution results in reduced space at the inter-domain interface in 6cesD. This figure shows the same structure as G after introduction of the Ala1395Thr variant by in silico mutagenesis. Quantitative results are given in Supplementary material 18. Analysis of DEPDC5 from PDB 6cet is shown in Supplementary Fig. 1
Figure 3 FCD and details of DEPDC5 variant. (A) Brain MRI showing FCD. Coronal T1-weighted brain MRI from Case 1-102398, with DEPDC5 variant NM_001242896.3:c.G4183A:p.A1395T, showing left temporal lobe FCD (right of patient is on the left of the image, following radiological convention), with blurred grey–white interface and cortical thickening apparent in the left temporal lobe across several consecutive slices. (B) MetaDome map of regional constraint in DEPDC5. Grey bar below the graph represents the protein, pink bars showing Pfam domains: PF12257, Vacuolar membrane-associated protein Iml1 domain; PF00610, Domain found in Dishevelled, Egl-10, and Pleckstrin (DEP); A1395 is marked by a vertical green line, with a reported tolerance score of 0.28 (‘intolerant’). (C) VarSite sequence logo for DEPDC5 residues 1375–1414, based on alignment of structural homologues; below the logo is the sequence of DEPDC5 itself, with A1395 boxed; sequence conservation score for this residue was 0.92 [range 0 (low)–1 (high)]; alanine was observed at this position in 31/33 aligned sequences. (D) Structure of the GATOR1-Rag GTPases complex and context of DEPDC5 Ala1395. PDB 6ces, the structure of the heterotrimeric GATOR1 complex (DEPDC5:NPRL2:NPRL3) bound to RagA and RagC GTPases; protein surfaces shown by colour as indicated (except DEPDC5, shown as a ribbon and coloured by structural domains as annotated by Shen et al.39: bright green = N-terminal domain (NTD) (residues 38–165); cyan = SABA domain (166–425); orange = steric hindrance for enhancement of nucleotidase activity (SHEN) domain (721–1010); dark green = DEP domain (1175–1270); violet = C-terminal domain (CTD) (1271–1600); Ala1395 is pink with sidechain atoms shown as spheres. (E and F) Ala1395 lies at an inter-domain interface in DEPDC5. The figure shows selected residues of DEPDC5 from PDB 6ces (chain D); residues of the NTD, SABA domain and CTD are shown as separate surfaces; residues of the SHEN domain and DEP domain are shown as ribbons. F shows the same structure as E with SHEN and DEP domains removed; residues Tyr108 (bright green), Phe326 (blue) and Ala1395 (rose pink) lie in close proximity at a three-way interface between the NTD, SABA and CTD. (G) Enlarged image of the DEPDC5 structure (PDB 6ces, chain D) as in E and F, zoomed to show detail around the three-way interface between the NTD, SABA and CTD; (H) The Ala1395Thr substitution results in reduced space at the inter-domain interface in 6cesD. This figure shows the same structure as G after introduction of the Ala1395Thr variant by in silico mutagenesis. Quantitative results are given in Supplementary material 18. Analysis of DEPDC5 from PDB 6cet is shown in Supplementary Fig. 1CC BY · PubMed Central
Figure 4 PRS applied across the cohorts. (A) Polygenic risk score (PRS) for intelligence was lower in the Dravet syndrome cohort than in GEL Epilepsy (adjusted P = 0.0024) and GEL control cohorts (adjusted P = 0.003). The difference between GEL Epilepsy and GEL controls was not significant (adjusted P = 0.69). (B) PRS for longevity was significantly higher in the Dravet syndrome cohort than in GEL Epilepsy controls (adjusted P = 0.011), and higher than, but not significant, in GEL controls (adjusted P = 0.024) and not significantly different in GEL Epilepsy controls compared to GEL controls (adjusted P = 0.68). (C) PRS for epilepsy was not significantly different in the Dravet syndrome cohort compared with the GEL controls (adjusted P = 0.89) and GEL Epilepsy controls (adjusted P = 0.11). PRS for epilepsy was significantly higher in the GEL Epilepsy controls than in the GEL controls (adjusted P < 2.22 ×10−16). The per-PRS P-values shown in the graphics are estimated using a post hoc multiple pairwise comparison (Tukey’s test). As multiple PRS analyses were performed, the final adjusted P-value significance threshold was set to α = 0.05/3. GEL = Genomics England.
Figure 4 PRS applied across the cohorts. (A) Polygenic risk score (PRS) for intelligence was lower in the Dravet syndrome cohort than in GEL Epilepsy (adjusted P = 0.0024) and GEL control cohorts (adjusted P = 0.003). The difference between GEL Epilepsy and GEL controls was not significant (adjusted P = 0.69). (B) PRS for longevity was significantly higher in the Dravet syndrome cohort than in GEL Epilepsy controls (adjusted P = 0.011), and higher than, but not significant, in GEL controls (adjusted P = 0.024) and not significantly different in GEL Epilepsy controls compared to GEL controls (adjusted P = 0.68). (C) PRS for epilepsy was not significantly different in the Dravet syndrome cohort compared with the GEL controls (adjusted P = 0.89) and GEL Epilepsy controls (adjusted P = 0.11). PRS for epilepsy was significantly higher in the GEL Epilepsy controls than in the GEL controls (adjusted P < 2.22 ×10−16). The per-PRS P-values shown in the graphics are estimated using a post hoc multiple pairwise comparison (Tukey’s test). As multiple PRS analyses were performed, the final adjusted P-value significance threshold was set to α = 0.05/3. GEL = Genomics England.CC BY · PubMed Central
Figure 5 PRS applied across the GEL SCN1A control and Dravet syndrome cohorts. (A) Polygenic risk score (PRS) for intelligence was lower, but not significant, in the Dravet syndrome cohort than in GEL SCN1A controls (adjusted P = 0.033). (B) PRS for longevity was higher, but not significant, in the Dravet syndrome cohort than in GEL SCN1A controls (adjusted P = 0.049). (C) PRS for epilepsy was not significantly different between the Dravet syndrome cohort and GEL SCN1A controls (adjusted P = 0.28). Black circles = individuals from the GEL SCN1A control cohort with variants previously reported to be associated with disease. The per-PRS P-values shown in the graphics are estimated using a post hoc multiple pairwise comparison (Tukey’s test). As multiple PRS analyses were performed, the adjusted P-value significance threshold was set to α = 0.05/3. GEL = Genomics England.
Figure 5 PRS applied across the GEL SCN1A control and Dravet syndrome cohorts. (A) Polygenic risk score (PRS) for intelligence was lower, but not significant, in the Dravet syndrome cohort than in GEL SCN1A controls (adjusted P = 0.033). (B) PRS for longevity was higher, but not significant, in the Dravet syndrome cohort than in GEL SCN1A controls (adjusted P = 0.049). (C) PRS for epilepsy was not significantly different between the Dravet syndrome cohort and GEL SCN1A controls (adjusted P = 0.28). Black circles = individuals from the GEL SCN1A control cohort with variants previously reported to be associated with disease. The per-PRS P-values shown in the graphics are estimated using a post hoc multiple pairwise comparison (Tukey’s test). As multiple PRS analyses were performed, the adjusted P-value significance threshold was set to α = 0.05/3. GEL = Genomics England.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 78 references

Cited by

See all 62

Metadata

Authors
Martins Custodio, H., Clayton, L. M., Bellampalli, R., Pagni, S., Silvennoinen, K., Caswell, R., Genomics England Research Consortium, Ambrose, J. C., Arumugam, P., Bevers, R., Bleda, M., Boardman-Pretty, F., Boustred, C. R., Brittain, H., Brown, M. A., Caulfield, M. J., Chan, G. C., Giess, A., Griffin, J. N., Hamblin, A., Henderson, S., Hubbard, T. J. P., Jackson, R., Jones, L. J., Kasperaviciute, D., Kayikci, M., Kousathanas, A., Lahnstein, L., Lakey, A., Leigh, S. E. A., Leong, I. U. S., Lopez, J. F., Maleady-Crowe, F., McEntagart, M., Minneci, F., Mitchell, J., Moutsianas, L., Mueller, M., Murugaesu, N., Need, A. C., O'Donovan, P., Odhams, C. A., Patch, C., Perez-Gil, D., Pereira, M. B., Pullinger, J., Rahim, T., Rendon, A., Rogers, T., Savage, K., Sawant, K., Scott, R. H., Siddiq, A., Sieghart, A., Smith, S. C., Sosinsky, A., Stuckey, A., Tanguy, M., Tavares, A. L. T., Thomas, E. R. A., Thompson, S. R., Tucci, A., Welland, M. J., Williams, E., Witkowska, K., Wood, S. M., Zarowiecki, M., Brunklaus, A., Guerrini, R., Koeleman, B. P. C., Lemke, J. R., Møller, R. S., Scheffer, I. E., Weckhuysen, S., Zara, F., Zuberi, S., Kuchenbaecker, K., Balestrini, S., Mills, J. D., & Sisodiya, S. M.
Affiliations
  • University College London Queen Square Institute of Neurology, Department of Clinical and Experimental Epilepsy , London, WC1N 3BG , UK
  • UCL Queen Square Institute of Neurology (GB)
  • Kuopio University Hospital (FI)
  • Royal Devon University Healthcare NHS Foundation Trust (GB)
  • Istituto Giannina Gaslini (IT)
  • Royal Hospital for Children (GB)
  • Meyer Children's Hospital (IT)
  • University Medical Center Utrecht (NL)
  • University Hospital Leipzig (DE)
  • University of Southern Denmark (DK)
  • Royal Children's Hospital (AU)
  • University of Antwerp (BE)
  • University College London (GB)
  • Amsterdam Neuroscience (NL)
Corresponding author
Sisodiya, Sanjay M
Venue
Brain
Published
2023-04-03
Volume
146
Issue
9
Pages
3885-3897
ISSN
  • 0006-8950 (ISSN-L)
  • 1460-2156
OpenAlex
W4362505742
Cited by
62
References
78
Citations by year
2026: 14 · 2025: 22 · 2024: 19 · 2023: 7
FWCI
12.57
Type
journal article
Language
en
Open access
Locations
  • Brain (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, public-domain)
  • UCL Discovery (University College London) (submittedVersion, cc-by)
  • Florence Research (University of Florence) (submittedVersion, public-domain)
  • Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
  • CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion, other-oa)
  • Royal Devon and Exeter Research Repository (Royal Devon and Exeter) (submittedVersion)
  • University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion, cc-by)
Funders
  • Wellcome Trust Strategic Award (WT104033AIA)
  • The Muir Maxwell Trust
  • The Amelia Roberts Fellowship
  • The Fidelity Foundation
  • Dravet syndrome UK
  • The Wellcome Trust, Cancer Research UK
  • Medical Research Council
  • National Institute for Health Research
  • University College London Hospitals Biomedical Research Centre
  • UK Department of Health’s NIHR Biomedical Research Centres
Topics
  • Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion channel regulation and function
Keywords
Dravet syndrome, SCN1A, loss-of-function mutations, phenotypic heterogeneity, rare variants, DEPDC5, focal cortical dysplasia, polygenic risk score, intelligence, longevity, premature mortality
MeSH terms
Epilepsy, Epilepsies, Myoclonic, Humans, Phenotype, Genomics, NAV1.1 Voltage-Gated Sodium Channel

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Widespread genomic influences on phenotype in Dravet syndrome, a ‘monogenic’ condition. https://app.cochat.ai/papers/10.1093/brain/awad111
The paper
Martins Custodio, H., Clayton, L. M., Bellampalli, R., Pagni, S., Silvennoinen, K., Caswell, R., Genomics England Research Consortium, Ambrose, J. C., Arumugam, P., Bevers, R., Bleda, M., Boardman-Pretty, F., Boustred, C. R., Brittain, H., Brown, M. A., Caulfield, M. J., Chan, G. C., Giess, A., Griffin, J. N., . . . Sisodiya, S. M. (2023). Widespread genomic influences on phenotype in Dravet syndrome, a ‘monogenic’ condition. Brain. https://doi.org/10.1093/brain/awad111

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.